Health
Dupilumab considerably reduced asthma exacerbations in young children, shows VOYAGE trial – News-Medical.Net
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled…
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference. VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.
Dupilumab also rapidly improved lung function…
-
Business18 hours agoThis leading broker thinks the CSL share price can climb 40%
-
Business10 hours agoDicker Data rides the AI trend to double digit growth
-
Business14 hours agoThis ASX 200 healthcare stock crashed 14% to 4-year low. Here’s what happened
-
General23 hours agoDenmark summons US envoy over suspected influence operations in Greenland